Huadong Medicine and Sanegene Bio Announce Strategic Collaboration to Co-Develop siRNA Therapeutics for Chronic Metabolic Diseases

According to Huadong Medicine, on November 9, Huadong Medicine's wholly-owned subsidiary, Huadong Medicine Co., Ltd., reached a strategic cooperation with Suzhou SANEGENEBIO. Based on SANEGENEBIO’s innovative LEADTM (Ligand and Enhancer Assisted Delivery) technology platform, both parties will jointly develop siRNA drugs targeting chronic metabolic diseases and further explore opportunities for collaboration in developing novel siRNA drugs in other therapeutic fields.